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An economic model to value companion diagnostics
in non-small-cell lung cancer
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Aim: An economic model was used to evaluate the potential economic impact and cost–effectiveness of
companion diagnostic testing for patients with non-small-cell lung cancer (NSCLC). Materials & methods:
A decision analysis model examined alternative patient management strategies for patients with advanced
NSCLC who were not amenable to surgical treatment. A review of the literature provided the variables
used to develop a timely base case and sensitivity analysis. A potential future scenario was also modeled.
The model includes three options: conventional treatment (CT), new treatment (NT), and companion
diagnostic (CD) strategy. Results: In the base case analysis based upon current data, the cost per life-year
saved for CT, NT option and CD was US$43,367, US$47,394 and US$47,779, respectively. The cost per lifeyear saved for CT, NT option and CD in a potential future scenario with more expensive, effective targeted
therapy was US$47,748, US$69,255 and US$66,369, respectively. Conclusion: In the future scenario, CDs
have an incremental cost–effectiveness of US$56,829 per life-year saved when compared with NT as a
first-line treatment. This is one demonstration of how CDs may be a cost-effective option for the treatment
of patients with advanced NSCLC when the NT is extremely expensive but the outcome is significantly
improved.
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diseases [3] . From an economic standpoint, the
cost–effectiveness of a CD test for NSCLC is
likely to depend upon such factors as the prevalence of a particular molecular mutation associated with therapeutic response, expected life
expectancy, and the costs of available treatment
and testing strategies.
Newer chemotherapeutic agents often benefit
specific subgroups of patients who possess specific clinical, pathological and molecular characteristics [4] . As the ability to identify the cancer genome improves with the use of CD tests,
clinicians may be increasingly able to identify
those characteristics in advance and target
therapy towards those patients most likely to
benefit from a particular treatment. For example, the molecular marker for the EGFR driver
mutation predicts a better overall prognosis and
response to tyrosine kinase inhibitors erlotinib
and gefitinib and has a frequency in a nonenriched US group of approximately 18% [5] .
The EML4–ALK fusion oncogene (frequency:
~4%), and more recently ROS1 (frequency:
1.7%) represent novel molecular targets predicting sensitivity to the drug crizotinib [6] .
New markers are rapidly appearing, offering
novel targets for therapy in a selected proportion of lung cancer patients with a higher likelihood of response than nonselective therapies.
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Lung cancer is among the most common neoplastic diseases encountered across the world
and has among the highest rates of death
amongst all cancer patients. The cost of treating lung cancer has also risen significantly, and
as novel therapies emerge, the costs will most
certainly rise as these novel agents are incorporated into clinical practice [1,2] . Most lung
neoplasms (85%) are non-small-cell lung cancer (NSCLC) and patients with NSCLC often
present at a mid to late stage, when treatment
modalities are predominantly nonsurgical and
palliative versus curative and directed towards
symptom control and maintenance of a reasonable functional status and quality of life [1] .
In view of the potential for significant adverse
events with chemotherapy, and the high cost of
potential targeted molecular therapies, companion diagnostics (CDs) could be potentially
valuable in identifying those NSCLC patients
most likely to benefit from a particular chemotherapeutic agent. A CD-guided patient
management strategy, in which patients who
possess a particular driver mutation associated
with a better clinical outcome in response to a
certain drug are identified in advance to target
treatment towards those most likely to benefit, may represent a cost-effective option for
emerging novel therapies for NSCLC and other
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the strategy that targets current and emerging molecular therapies for NSCLC. Current
molecular therapies, for example, include the
EGFR tyrosine kinase inhibitors such as erlotinib [10] , and anaplastic lymphoma kinase
inhibitors such as crizotinib [11] . We assumed
that the CD tests for the presence of markers associated with the effectiveness of current
molecular therapies. The model was designed to
encompass novel CDs and molecular therapies
that may be developed in the future.
One key clinical question that could require
analytical modeling is not whether to employ
the diagnostic test, but how best to select
patients for testing. The CD strategy included
the use of a test, such as an immunohisto
chemistry or genomic test, that guides the next
step in the treatment process [10] . The model for
NSCLC used in this study was generic in order
to admit scenarios of both current and emerging chemotherapy drugs and tests. Our model
investigated the effect of a paradigm shift
where providers select one treatment strategy
over another, in this case by choosing NT or
CD instead of CT. While some patients may
already receive diagnostic testing, we modeled
the move from CT as the standard of care to
NT or CD.
Our model incorporated costs and outcomes
for a number of therapies, both in the CT and
NT arms of the study. Costs and outcomes of
CT included costs of docetaxel or pemetrexed,
as well as other approved therapies as detailed
in the ‘Variable selection’ section below. Costs
and outcomes of NT included erlotinib, as
well as other approved therapies. No single
therapy was investigated in this study. Rather,
any therapies that have the outcome and cost
characteristics of the therapies used to populate
this study can be investigated with the model
we developed and analyzed.
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Materials & methods
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The goal of using a CD-guided strategy is to
tailor the treatment strategy for each patient to
improve expected survival, minimize the risk of
potential side effects, and, from an economic
standpoint, maximize the cost–effectiveness of
scarce healthcare resources [7] .
As with any patient management strategy,
the attractiveness of CDs depends upon the
net expected benefit that that test provides and
the clinical decisions that ensue from the test
result. In general, the main incremental benefit
of a CD test for a particular disease is the selection and stratification of those patients who will
most likely benefit from a particular therapeutic strategy [8] . From an economic standpoint, this approach has several ramifications
regarding resource use and efficiency, because
any approach that increases the efficient use
of scarce resources will likely be cost effective
by comparison. We therefore developed a general model to test the clinical and economic
impact and cost–effectiveness of a CD strategy
for patients with NSCLC.
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Model technique
A decision-analysis model was developed for a
baseline population of NSCLC patients. The
patient population had nonresectable, advanced
disease (stages III–IV), in which the patient’s
status allowed for treatment beyond palliation.
The model assumed the perspective of a managed care payer in the USA with a 1‑year time
horizon. A managed care perspective was used
to set the 1‑year time horizon for the model.
The method that we used to set up costs
incurred in the model is consistent with the
cost structure of fee-for-service Medicare. In
order to make our results generalizable to other
contexts, the model could be extended beyond
the 1‑year time horizon, as we demonstrate in
an alternative future scenario. We chose not to
include in our analysis societal costs such as
time missed at work or quality-adjusted lifeyears. Researchers might want to broaden the
context to a full societal perspective, and could
do so with this model.
The patient population and perspective led
to the inclusion of three clinical strategies in
the model: conventional treatment (CT), new
treatment (NT) option and a CD strategy. We
defined CT to refer to the current standard of
practice for late-stage NSCLC, which generally includes cisplatin-based (or platinumbased) combination therapy with docetaxel or
pemetrexed [9] . The NT option was defined as
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Model structure & description
the decision-tree model employed
in this analysis. The model depicts three main
arms that correlate with the three strategies,
CT, NT and CD, which are described above.
Our model consolidated the many possible
clinical pathways embedded in these three
strategies into a small number of possible outcomes. TreeAge Pro 2009 was used to develop
and depict the decision tree and perform the
associated analyses [101] .
In the CT strategy, we assumed that all
patients would receive and remain on CT and
that no diagnostic test for molecular markers
Figure 1 shows
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Figure 1. Decision tree model.
Tx: Treatment.
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equally available for all NSCLC cancer patients
regardless of treatment line.
The CD strategy incorporated the use of
a CD test, prior to the administration of any
chemotherapy, to identify those patients who
have a genetic or molecular mutation that has
been associated with improved outcomes. We
assumed, for the purposes of this analysis, that
the results from this test would be dichotomous
(i.e., positive or negative). Patients who tested
positive initially received the NT. They were
then evaluated to determine their response to
NT. If they responded, NT was continued. If
they did not respond, they were switched to CT.
Patients who tested negative were assigned to
CT and we further assumed that they would
never receive the new molecular therapy that
was tested for, regardless of eventual response.
The model is generalizable in that it can
incorporate the results of tests that examine
one marker or several markers in combination.
This is important for CDs, which are not billed
as such but rather by ‘stacking’ multiple billing
codes for each aspect of the test. In other words,
each activity that comprises the test is billed to
the payer separately. The provider or laboratory cannot bill for the entire test with a single,
unified procedure code. The variable selection
used EGFR and ALK gene tests in developing
the outcomes and costs input into the model
(see ‘Variable selection’ section). However,
our model was not specific to any marker or
combination of markers.
The expected outcomes of the CD strategy
depended on several variables. The CD, CT
and NT costs, the time at which patients are
re-evaluated, the response rate of patients to
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would be performed. The outcomes of this
branch depended on the costs associated with
the CT itself and all other medical costs
incurred by patients throughout the course
of care. To simplify the model structure, we
incorporated such parameters as the re-evaluation of the effectiveness of chemotherapy,
adverse events and mortality probabilities of
chemotherapy, as opposed to designing separate
branches.
The NT strategy referred to the use and
administration of a novel molecular-based therapy to all patients who may potentially benefit
without the use of a diagnostic test to identify potential driver mutations associated with
increased likelihood of benefit. We structured
into this arm a period of months following therapy, after which, patients are re-evaluated [12] .
Patients would remain on this therapy if they
demonstrated an objective beneficial response
and would be switched to CT if they failed to
respond or the tumor progressed. The expected
outcomes from this strategy incorporated: the
cost of NT; the cost of CT; the time at which
patients are re‑evaluated; the response rate of
patients to the NT; the survival of responsive
patients; and the survival of nonresponsive
patients. As before, we also incorporated the
probabilities of adverse events and mortalities directly into the model rather than creating separate ‘sub-branches’ for these potential
sequelae. It is important to note that these
drugs have not been approved by the US FDA
for use in first-line NSCLC cancer treatment.
Our model demonstrated how to evaluate the
cost–effectiveness of diagnostics in a scenario
where CT and molecular therapy would be
future science group
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Table 1. Probability variables from the literature used to populate
the model.
Variable

Probability

Ref.

Sensitivity

0.92

Specificity

0.96

[16]

Prevalence

0.19

[17]

Positive predictive value

0.84

Calculated based on
assumed sensitivity,
specificity and
prevalence

Negative predictive value

0.98

Calculated based on
assumed sensitivity,
specificity and
prevalence

New treatment – unselected response
rate

0.34

[18]

New treatment – selected response rate 0.66

[18]

[16]

of

†

and their sources in the literature are presented in Table 2 . All costs were brought forward to 2011 using the Consumer Price Index
(CPI)–Urban Medical inflation factor [102] .
The test costs were derived from average costs
reported in the references used in the paper. We
chose the medical CPI as the index that best
reflects the therapies and technologies analyzed
in this study. We also note that our model is
general enough to admit other inflation factors, such as the CPI–Urban and other medical
trend factors.
The final type of variable needed was survival. The survival values and their sources in
the literature are presented in Table 3. In order
to fit the 1‑year time horizon of the model
used in this study, 1‑year survival data was
extracted from the overall survival presented
in the published studies.
These assumptions were entered into the
model deterministically and did not follow
the cost–effectiveness practice standards that
would be required for a full cost–effectiveness
analysis of a specific diagnostic and specific
therapies. We would recommend that any ana
lysis utilizing this model follow the appropriate guidelines for cost–effectiveness analysis,
and consider such an analysis on specific tests
and therapies to be a follow-up study to this
analysis. Current literature suggested there is
no evidence of an overall survival benefit from
selecting treatment on the basis of EGFR status. We followed this assumption in selecting
variables for our model.

We chose a specificity slightly below the one used in the article in order to perform sensitivity
analysis.

ro

†

rP

the NT, the survival of responsive and nonresponsive patients, and the prevalence of the
mutation in the patient population, along with
the sensitivity and specificity of the CD test,
were all part of the model. The derivation of
the associated variables is described in the next
section.
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Variable selection
The first type of variable required to populate
the generic model was probability. The probability values and their sources in the literature
are presented in Table 1. In our case of a CD, the
meaning of sensitivity and specificity were in
relation to the dichotomous presence or absence
of the mutation. The prevalence of a generic
mutation was based on a single driver mutation
that was present in some but not all patients’
cancers. The probability of response can be
unselected (meaning for the entire population)
or selected (meaning for those who test positive). Probability of response in the CT arm was
included in the overall survival outcomes data.
The second type of variable needed to
populate the model was costs. Cost variables

Table 2. Cost variables from the literature used to populate the
model.
Variable

Cost (US$)

Ref.

Conventional treatment – second line

3979/month

[19]

New treatment – second line

3125/month

[19]

Test

470

[13]

†

We used second-line costs for consistency because first-line costs were not available for the new
treatment.

†
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Results

Deterministic results
The end points of our model included the
expected outcomes of both cost and survival,
resulting in a cost–effectiveness ratio for each
strategy. The outcome measure of cost per year
of life saved was calculated for each individual
strategy. The cost per life-year saved for each
strategy was used to calculate an incremental
cost–effectiveness ratio (ICER). The ICER
compares the relative cost–effectiveness of the
NT, CD and CT strategies.
T a bl e 4 shows the current base results.
The strategies resulted in similar clinical
outcomes (~0.4–0.5 life-years saved) and
costs (~US$19,000–22,000). The resulting
cost–effectiveness of the strategies were similar
(~US$43,000–48,000 per life-year saved). As
a result, the cheapest strategy, NT, dominated
CT. The incremental cost–effectiveness of CD
was approximately US$155,000 per life-year
future science group
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saved. It is likely the CD ICER estimates
were driven by potential alterations in costs of
treatment rather than survival benefits.

Table 3. Cost variables from the
literature used to populate the model.
Variable

Months


Sensitivity analyses
We generated a more in-depth view of the
importance of different variables with one-way
sensitivity analysis. Intuitively, if one treatment
is very cheap, or very expensive, the CD might
not add economic value – we should just try the
cheap therapy, especially if neither is clinically
superior. That intuition comes through in the
sensitivity analysis, where varying the cost of
the new therapy changes the reference therapy
(Figure 2) . When the new therapy was cheap, the
new therapy strategy was the reference strategy, dominating the CT strategy. The CD
strategy had a high ICER, because it improved
outcomes, but at a relatively high cost.
As the new therapy became more expensive,
the CD strategy became more cost effective.
At a certain point, the new therapy became
expensive enough that the CT strategy was
the reference therapy. The conventional strategy was the least costly, followed by the NT
strategy, followed by the CD strategy. The
incremental cost–effectiveness of the two more
costly strategies was more reasonable, and the
CD continued to decline. The incremental
cost–effectiveness of the NT strategy rose until
it became uneconomical.
Above a certain value, the NT for all strategy is more costly and less effective than the
CD strategy. In this range, the CD strategy
dominates the NT for all strategy. The CT
strategy continued to be the reference, and the
CD strategy rose again. The cost–effectiveness
of the CD strategy was discontinuous, and it
was a more cost-effective strategy for middle
values of the NT compared with extremely high
or low values.
Table 5 shows an additional sensitivity ana
lysis based on the current base case. The cost
of the NT was increased by 15%, resulting in
increased costs for the NT and CD strategies.
There were no changes in clinical outcomes.
The order of strategies from least to most costly

Conventional treatment

5.63

[20]

New treatment – unselected

5.26

[21]

New treatment – selected

7.66

[22]
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changed to CT, NT and CD, respectively. NT
had an ICER of US$53,609 when compared
with CT, and CD had an ICER of US$73,201
when compared with NT.
Table 6 shows the variables used for a future
scenario, the results of which are in Table 7. The
future scenario represented a possible future
where a small number of individuals would be
expected to receive radically greater benefits
from NT, and where that NT would be targeted
through CDs. This hypothetical scenario was
based on the desire to show how breakthrough
therapies that extend survival well beyond
those currently available would fit our model
and change our results. It addressed the future
perspective where novel therapies may be highly
effective yet costly.
There was a very small, essentially negligible, difference in the effectiveness between
these two strategies in Table 7. NT was slightly
more effective; however, this difference was
not shown when rounding to two decimal
places. This led to the appearance of a high
ICER for NT, which was due to the nonlinear
effect of changing the inputs on the outputs
in our model. Thus, the NT strategy became
slightly less effective although the CD strategy
showed remarkably greater clinical outcomes.
The order of strategies from least to most costly
was CT, NT and CD as in the current sensitivity analysis shown above. NT had an ICER
of US$6,184,134 when compared with CT,
and CD had an ICER of US$56,829 when
compared with NT.
Other sensitivity analyses included changing
the cost of the CD. We choose to highlight two
point estimates in the manuscript. One is the
test cost that we estimated from the literature.
The second is a low estimate that is used to

Table 4. Cost–effectiveness results under the future scenario.
Strategy

Cost (US$)

LYS

Cost/LYS (US$) ICER

New treatment

19,464

0.45

43,367

Reference

Companion diagnostic

22,070

0.47

47,394

US$154,512

Conventional treatment

20,930

0.44

47,779

Dominated (more expensive,
less effective then reference)

ICER: Incremental cost–effectiveness ratio; LYS: Life-years saved.
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Figure 2. Sensitivity analysis of new treatment cost.
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highlight the small impact of changes in test
cost on the result. For example, US$114 was the
average Medicare reimbursement for a generic
immunohistochemistry test [13] . The ranks and
magnitudes of the results were not changed for
the range of test costs from US$114 to US$470,
which did demonstrate the relative insensitivity
of results to the cost of the CD test itself (results
not shown).

A

Discussion
The model used is generalizable, and is able
to inform future economic evaluations of CDs
under many scenarios. The demonstration of
the economic modeling approach, applied to
a CD for NSCLC, and using published data
where possible, shows the potential of economics modeling to inform the use of CD strategies
in oncology. The information from a CD test is
intuitively valuable if it leads to different, more
personalized treatment based on the results of

the test. The model demonstrates quantitatively
the value of CD information. For example, one
economic rationale for the CD is efficient use
of costly novel therapies that may be developed,
which is shown by the future scenario (Table 7) .
The relative outcomes of the three strategies
also come from the 1‑year time horizon for
our model. The NTs we used are noninferior
to CTs (Table 3) , so the outcomes are similar.
There may be a justification for value in stratified treatment strategies in this case. We chose
not to model such strategies, as our goal was
to create a model that compared the strategies
independently. The small additional benefit in
survival of the CD in the current base case and
sensitivity analyses comes from the prevalence
of the mutation in a minority of the population.
The responsive patients live nearly 50% longer;
however, there are not enough to generate a
large improvement over the CT strategy. That
is a function of both the payer time horizon

Table 5. Current sensitivity analysis.
Strategy

Cost (US$)

LYS

Cost/LYS (US$)

ICER

Conventional treatment

20,930

0.44

47,749

Reference

New treatment

21,492

0.45

47,886

US$53,609

Companion diagnostic

22,726

0.47

48,802

US$73,201

ICER: Incremental cost–effectiveness ratio; LYS: Life-years saved.
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Table 6. Future scenario variables.
Variable

Value

Prevalence

40%

Population response

5%

False-positive response

5%

True-positive response

70%

New treatment monthly cost

US$7000

Survival for new treatment responders

11.5 months

ro

of

patients from a test that can potentially point
to a highly effective therapy.
This study demonstrates the need to model
the diagnostic and the therapy as a single, bundled product. It also shows how such a model
can be populated with data, and what results
will be generated. Currently, stakeholders are
debating whether drugs and the diagnostics that
test for them should be regulated together or
separately. They are also debating whether drugs
and the diagnostics that test for them should be
reimbursed and evaluated together or separately.
Thus, our study shows the cost–effectiveness
implications of the bundled strategy, which we
feel will become more important as the bundled
product model gains more currency. It may
also help stakeholders envision and decide on
bundled payments or value-based payments that
consider the costs of an entire episode of care,
rather than individual elements.
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in the USA and the severity of NSCLC in the
modeled patient population.
As a result, relatively small changes in costs
have large effects on cost–effectiveness results.
When the NT is cheap, the NT strategy is the
reference strategy, dominating the CT strategy.
The CD strategy has a high ICER, because it
improves outcomes at a relatively high cost. As
the NT becomes more expensive, the CD strategy becomes more cost effective. At a certain
point, the NT becomes expensive enough that
CT is the reference strategy.
The economic modeling study also shows
the amount of new data needed to populate
a model of CDs. A clinical trial might compare the three strategies (CT, NT and CD)
head-to-head. An ideal economic arm of the
study would collect the total costs of therapy
for the three groups. As the current sensitivity analysis demonstrates (Ta ble 5) , the total
cost of treatment for the NT or CT, including
adverse events and treatment switches, is the
critical variable for deriving the economic value
of CDs. Outcomes research should include
all costs including adverse events and medical claims, in order to demonstrate the true
economic value of CDs.
This evidence also informs the regulatory
approach to CDs. The simultaneous approval
of therapy and test advocated by the FDA is
a match for the way that the model evaluated
the CD [7] . The value of the test cannot
be separated from the associated therapy.
Furthermore, regulators, especially outside the
USA, will likely request this kind of economic
evaluation.
We also wish to contrast our results using
a CD strategy with the patient enrichment
strategy evaluated by other researchers. Based
on the American Society of Clinical Oncology
guidelines, all individuals are recommended
the use of EGFR tests to aid treatment decision-making for NSCLC. There is a dispute
as to how to utilize this information. A CD
approach utilizes the test for all patients at a
given stage to separate the recommended treatment. By contrast, the ‘patient enrichment’
strategy investigated by Atherly and Camidge
used population data to try to find a population
where the prevalence of the marker or markers is likely to be much higher, and to restrict
the test to those subpopulations [14] . Since the
tests and therapies modeled in this analysis are
novel, we feel that the CD strategy is the one
more likely to be used, as it may be difficult or
impossible to restrict NSCLC or any cancer
future science group

Conclusion
The economic evaluation of CDs differs somewhat from the standard comparative effectiveness evaluation of drugs. Our model, variables
from the literature, assumptions and sensitivity
analysis shows that CDs are valuable in a situation where a highly valid test can separate a
patient population into two groups. The literature review-based data shows how CD extends
the life of a selected population beyond that
which is enjoyed by the average member of the
population. The additional survival data alone
is not enough for economic evaluation. The cost
of the two types of treatment, including adverse
events and supportive care, is also important.
Table 7. Future scenario.
Strategy

Cost (US$) LYS

Cost/LYS (US$) ICER

Conventional treatment 20,930

0.44

47,748

Reference

New treatment

30,464

0.44

69,255

US$6,184,134

Companion diagnostic

38,020

0.57

66,369

US$56,829

ICER: Incremental cost–effectiveness ratio; LYS: Life-years saved.
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The numerical results of this study may not
generalize to other clinical contexts or future
NSCLC therapies.
The model we develop and present can
encompass a range of future NSCLC therapies
that may be developed. Our future scenario is
one way of looking at how the results change
when selection on the basis of a marker or markers generates significant overall survival benefit.
This generic model shows one path forward for
making the economic case for CDs.

of treatments attempted [15] . The result will be
a greater survival probability for lung cancer
where the expense of care is incurred over a
longer period. Careful economic analysis will
be needed to show that the increased clinical
benefit comes at an affordable cost.
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Future perspective
CDs may be the technology that delivers the
promise of personalized medicine for the treatment of NSCLC. While efforts towards prevention and early detection show some promise,
NSCLC will continue to be a late-stage disease
for many patients. The promise of new targeted
therapies is the ability to turn the disease from
terminal disease into a serious, but chronic, condition. For that reason, biopharmaceutical companies will continue to develop new targeted
therapies. However, regulators and payers will
continue to insist on showing the clinical effectiveness of these therapies, as well as the value
proposition for their use.
We anticipate that an increasing number of
these therapies will be approved for use in concert with CD tests. This will require a more
collaborative approach by biopharmaceutical
companies, especially those with a specialty
in molecular therapies or diagnostics, but not
both. It may also require a change in behavior by oncologists, such as limiting the number

Executive summary

A

Non-small-cell lung cancer care includes novel biopharmaceuticals
 Tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors are two types of targeted molecular therapies.
 More molecular therapies will be developed.
Science of companion diagnostics shows that there are multiple types of non-small-cell lung cancer
 Different types of patients have radically different responses to therapies.
 Companion diagnostics can identify these responses ahead of time.
Personalized medicine for oncology
 Knowing who will benefit ahead of time allows clinicians to improve care.
 Knowledge of which patients will benefit ahead of time allows clinicians to restrict the use of expensive novel therapies to those who
will benefit.
Economic case for companion diagnostics
 Companion diagnostics have a low cost relative to the overall cost of non-small-cell lung cancer therapy.
 The value of companion diagnostics is based on the improvements in care and the costs of suboptimal care that are avoided.
Conclusion
 Companion diagnostics are linked to the treatments they test for.
 Advancements in the science of companion diagnostics and biopharmaceuticals will require better economic data and additional
comparative effectiveness analyses.

146

Personalized Medicine (2013) 10(2)

future science group

An economic model to value companion diagnostics in non-small-cell lung cancer

n

Papers of special note have been highlighted as:
n of interest
nn of considerable interest

5

6

7

nn

8

Papadopoulos N, Kinzler KW, Vogelstein B.
The role of companion diagnostics in the
development and use of mutation-targeted
cancer therapies. Nat. Biotechnol. 24(8),
985–995 (2006).
Bell DW, Lynch TJ, Haserlat SM et al.
Epidermal growth factor receptor mutations
and gene amplification in non-small-cell lung
cancer: molecular analysis of the
IDEAL/INTACT gefitinib trials. J. Clin.
Oncol. 23(31), 8081–8092 (2005).
Bergethon K, Shaw AT, Ou SH et al. ROS1
rearrangements define a unique molecular
class of lung cancers. J. Clin. Oncol. 30(8),
863–870 (2012).

Herbst RS, Heymach JV, Lippman SM. Lung
cancer. N. Engl. J. Med. 359(13), 1367–1380
(2008).

11

Shaw AT, Yeap BY, Solomon BJ et al. Effect of
crizotinib on overall survival in patients with
advanced non-small-cell lung cancer
harbouring ALK gene rearrangement: a
retrospective analysis. Lancet Oncol. 12(11),
1004–1012 (2011).

12

13

14

nn

Becker R, Mansfield E. Companion
diagnostics. Clin. Adv. Hematol. Oncol. 8(7),
478–479 (2010).

15

n

Regulatory perspective on companion
diagnostics and the concurrent approval of
diagnostics and the therapies they test for.

Ferrara J. Personalized medicine: challenging
pharmaceutical and diagnostic company
business models. Mcgill J. Med. 10(1), 59–61
(2007).

future science group

16

17

Janne PA, Johnson BE. Effect of epidermal
growth factor receptor tyrosine kinase domain
mutations on the outcome of patients with
non-small-cell lung cancer treated with
epidermal growth factor receptor tyrosine
kinase inhibitors. Clin. Cancer Res. 12(14),
4416S-4420S (2006).

18

Janne PA, Wang XF, Socinski MA et al.
Randomized Phase II trial of erlotinib (E)
alone or in combination with
carboplatin/paclitaxel (CP) in never or light
former smokers with advanced lung
adenocarcinoma: CALGB 30406. J. Clin.
Oncol. 28(15s), Abstract 7503 (2010).

19

Ramsey SD, Martins RG, Blough DK et al.
Second-line and third-line chemotherapy for
lung cancer: use and cost. Am. J. Manag. Care
14(5), 297–306 (2008).

of

4

Opinion piece on the progress of
personalized medicine within oncology and
the prospects of personalized medicine
beyond oncology.

10

Eisenhauer EA, Therasse P, Bogaerts J et al.
New response evaluation criteria in solid
tumours: revised RECIST guideline
(version 1.1). Eur. J. Cancer 45(2), 228–247
(2009).

nn

20

VanHorn N, Bentley K. National Fee Analyzer
2010: Charge Data for Evaluating Fees
Nationally, Ingenix, USA (2009).

rP

nn

Bates S. Progress towards personalized
medicine. Drug Discov. Today 15(3–4),
115–120 (2010).

Azzoli CG, Baker S Jr, Temin S et al.
American Society of Clinical Oncology
Clinical Practice Guideline update on
chemotherapy for stage IV non-small-cell
lung cancer. J. Clin. Oncol. 27(36),
6251–6266 (2009).

Analysis of costs of care for lung cancer with
data about multiple types of treatments at
multiple stages of the disease.
Herbst RS, Prager D, Hermann R et al.
TRIBUTE: a Phase III trial of erlotinib
hydrochloride (OSI-774) combined with
carboplatin and paclitaxel chemotherapy in
advanced non-small-cell lung cancer. J. Clin.
Oncol. 23(25), 5892–5899 (2005).

Atherly AJ, Camidge DR. The
cost–effectiveness of screening lung cancer
patients for targeted drug sensitivity markers.
Br. J. Cancer 106(6), 1100–1106 (2012).

21

Maemondo M, Inoue A, Kobayashi K et al.
Gefitinib or chemotherapy for non-small-cell
lung cancer with mutated EGFR. N. Engl.
J. Med. 362(25), 2380–2388 (2010).

Model for cost–effectiveness utilizing a
‘patient-enrichment’ strategy.

22

Rosell R, Moran T, Queralt C et al. Screening
for epidermal growth factor receptor
mutations in lung cancer. N. Engl. J. Med.
361(10), 958–967 (2009).

ho

3

Warren JL, Yabroff KR, Meekins A et al.
Evaluation of trends in the cost of initial
cancer treatment. J. Natl. Cancer Inst.
100(12), 888–897 (2008).

9

ut

2

Bradbury PA, Tu D, Seymour L et al.
Economic analysis: randomized placebocontrolled clinical trial of erlotinib in
advanced non-small cell lung cancer. J. Natl.
Cancer Inst. 102(5), 298–306 (2010).

A

1

Analysis of how companion diagnostics will
challenge pharmaceutical and diagnostics
companies, and how collaborations can solve
these challenges.

ro

References

Research Article

Smith TJ, Hillner BE. Bending the cost curve
in cancer care. N. Engl. J. Med. 364(21),
2060–2065 (2011).
A perspective on the future of cancer care
under the new paradigms of cost
containment and more personalized
treatment.
Yu J, Kane S, Wu J et al. Mutation-specific
antibodies for the detection of EGFR
mutations in non-small-cell lung cancer. Clin.
Cancer Res. 15(9), 3023–3028 (2009).

www.futuremedicine.com


Websites
101 TreeAge Pro 2009 (Version release 1.0.2).

TreeAge Software, Inc., MA, USA (2009).
www.treeage.com
102 Bureau of Labor Statistics. Consumer Price

Index (CPI) 2011.
www.bls.gov/cpi

147

